Pharmafile Logo
Pharmafocus logo
Advanced Search

Nucala

Showing 11 posts of 11 posts found.

GSK’s Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups

November 13, 2019
Research and Development GSK, Nucala, pharma

GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary …

News
nucala-web

European approval for two new delivery formulations of GSK’s Nucala in severe eosinophilic asthma

August 2, 2019
Medical Communications, Sales and Marketing Europe, GSK, Nucala, asthma, pharma

Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, …

News

GSK’s Nucala data insufficient for US COPD approval

September 10, 2018
Sales and Marketing COPD, FDA, GSK, Nucala, US, pharma

GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …

News
astrazeneca-sign

AZ’s hopes for Fasenra in COPD suffer terminal blow

May 30, 2018
Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical

It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …

News

AZ’s Fasenra stumbles in P3 for COPD

May 11, 2018
Medical Communications, Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical

AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up …

News
shutterstock_291014192

NICE recommends GSK’s “first-in-class” asthma drug

November 30, 2016
Sales and Marketing GSK, NICE, Nucala, asthma

NICE has announced its recommendation of GSK’s “first-in-class” biologic Nucala (mepolizumab) as an extra option for the treatment of adults …

News
gsk_corp_hq_brentford_2

GSK’s Nucala gets regulatory approval in Japan to treat bronchial asthma

March 29, 2016
Manufacturing and Production, Research and Development GlaxoSmithKline, Japan, Nucala, US FDA, bronchial asthma

GlaxoSmithKline (LSE: GSK) on Tuesday said the Japanese regulators have approved its drug to treat bronchial asthma.  The Japanese Ministry …

News
gsk_corp_hq_brentford_2

GSK says long-term study for Nucala backs safety profile

March 8, 2016
Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, Nucala, asthma

UK pharma major GlaxoSmithKline (LSE: GSK) said its asthma drug, Nucala (mepolizumab) showed a similar safety profile in a long-term …

News
Nucala

Researchers question price of GSK’s Nucala

December 23, 2015
Research and Development GSK, HEOR, ICER, Nucala, asthma, cost-effective, health economics, health economics outcomes research

GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …

News
gsk_logo_with_text

GSK gets European approval for asthma treatment Nucala

December 3, 2015
Research and Development GSK, Nucala, asthma

GlaxoSmithKline has received marketing authorisation from the European Commission for Nucala as an add-on treatment for severe refractory eosinophilic asthma …

News
gsk_hq

GSK asthma drug Nucala gets FDA approval

November 6, 2015
GSK, Nucala, asthma, eosinophils, mepolizumab

GlaxoSmithKline has received approval from the FDA for Nucala as an add-on maintenance treatment of patients with severe asthma aged …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024